A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Treprostinil (Primary)
- Indications Diffuse scleroderma
- Focus Adverse reactions; Therapeutic Use
- 13 Oct 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.
- 13 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
- 13 Oct 2016 Status changed from not yet recruiting to recruiting.